Federal Register Notice: FDA has determined the regulatory review period for Johnson & Johnson’s Ortho-Evra is 2,001 days for the extension of a patent that claims that human drug product. Ortho-Evra (norelgestromin/ethinyl estradiol transdermal system) is indicated for the prevention of pregnancy. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce. To view this notice, click here.
